Close

Pulse Biosciences, Inc. (PLSE) Announces FDA Clearance for the CellFX System

Go back to Pulse Biosciences, Inc. (PLSE) Announces FDA Clearance for the CellFX System

Pulse Biosciences Announces FDA Clearance for the CellFX® System

February 3, 2021 9:00 AM EST

- CellFX System delivers Nano-Pulse Stimulation Technology in dermatologic procedures

- U.S. controlled launch to commence

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX® System for dermatologic procedures requiring ablation and resurfacing of the skin. In the coming weeks a controlled commercial launch in the U.S. will begin with a group of selected Key Opinion Leaders (KOLs) in aesthetic dermatology.

The CellFX... More